From the editor

Friday, December 23, 2016 Published in Impact October 2012 Written by Cepheid

Welcome to the fourth issue of IMPACT, the quarterly magazine published by Cepheid’s Systems & Solutions Group.

In this issue, Dr. Al Story and Dr. Rob Shorten share their particularly innovative and effective program for diagnosing tuberculosis in London. These two doctors are using an innovative Mobile X-Ray Unit (MXU) to improve TB diagnosis for hard-to-reach patients. This is the first example of a molecular diagnostic test being used in a mobile unit for near-patient testing anywhere in Europe.

Innovative Mobile X-Ray Unit and Xpert® MTB/RIF

Friday, December 23, 2016 Published in Impact October 2012 Written by Dr. Al Story, Clinical Lead for Find and Treat & Dr. Rob Shorten, Royal Free Hospital and University College London

The mobile x-ray unit (MXU) has been operating in London since 2005. It is staffed by TB nurse specialists, reporting radiographers, social workers and outreach workers. Its role is to identify hard-to-reach patients with suspected TB using digital chest radiograph. These patients, including individuals who are homeless or have substance abuse issues, are then linked into local healthcare provision via A&E or community TB programmes.

Improving Patient Safety

Friday, December 23, 2016 Published in Impact October 2012 Written by Jorge P. Parada, MD, MPH, FACP, FIDSA, Prof. of Medicine, Stritch School of Medicine Loyola University, Chicago

Loyola Meets the C. difficile Challenge

As noted in the June 2012 issue of Impact, there is a great deal of pressure on hospitals to be more accountable, and the pressure is only growing. Accountability reporting will impact hospital finances on multiple fronts: from reimbursement changes to patient hospital selection for elective procedures.

Needless to say, Healthcare associated infections (HAIs) are a key part of the accountability metrics required and soon-to-be required. In our first article, we explored Loyola University Hospital’s implementation of rapid, highly sensitive universal screening to successfully combat methicillin-resistant Staphylococcus aureus (MRSA).(1) In this article, we’ll look at how the hospital addressed another common and increasingly troublesome HAI: Clostridium difficile (C. difficile).

Inside Cepheid Innovation

Friday, December 23, 2016 Published in Impact October 2012 Written by Ron Chang, Cepheid Fellow and Doug Dority, Cepheid Fellow

Architecting Ease of Use

Ron and Doug first met when 12-year-old Ron was walking to a friend’s home one day and saw Doug taking apart a bike. The two have been building things together ever since. In this issue of IMPACT we sit down with Cepheid Fellows Doug Dority and Ron Chang as they discuss how they work together to help deliver unprecedented speed and ease-of-use with Cepheid’s molecular testing technology.

Just the Facts

Friday, December 23, 2016 Published in Impact October 2012 Written by Cepheid

FACT.

A USA Today investigation for an August 2012 cover story asserted that rates of death and illness from C. difficile infection are much higher than national reports have shown because the 14,000 deaths that the CDC reported in their most recent report are based on information from death certificates — which often don’t list C. difficile when patients die from complications of the infection, such as kidney failure.*